Free Trial

Jasper Therapeutics (JSPR) 10K Form and Latest SEC Filings 2026

Jasper Therapeutics logo
$0.97 -0.02 (-1.91%)
As of 03:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Jasper Therapeutics SEC Filings & Recent Activity

Jasper Therapeutics (NASDAQ:JSPR) has submitted 254+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 8-K submitted on March 30, 2026.

8-K
Jasper Therapeutics Files Current Report on Mar. 30, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Jasper Therapeutics Files Quarterly Report on Nov. 10, 2025

The 10-Q contains Jasper Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Jasper Therapeutics SEC Filing History

Browse Jasper Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
03/30/2026 4:33 PM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/25/2026 3:47 PM
INTEGRATED CORE STRATEGIES (0) US
Jasper Therapeutics (1788028) Subject
Form SCHEDULE 13G
02/12/2026 9:33 AM
GOLDMAN SACHS GROUP INC (886982) Filed by
Jasper Therapeutics (1788028) Subject
Form SCHEDULE 13G
02/11/2026 12:38 PM
Jasper Therapeutics (1788028) Subject
MORGAN STANLEY (895421) Filed by
Form SCHEDULE 13G
01/26/2026 2:29 PM
ACORN BIOVENTURES, L.P. (1766853) Filed by
Jasper Therapeutics (1788028) Subject
Form SCHEDULE 13G/A
01/08/2026 6:06 AM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 3:35 PM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2026 6:30 PM
CROSS HERB (1230721) Reporting
Jasper Therapeutics (1788028) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 6:30 PM
Jasper Therapeutics (1788028) Issuer
Mahal Jeetinder Singh (1882877) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 6:30 PM
Jasper Therapeutics (1788028) Issuer
MARTELL RON (1177079) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 9:23 AM
ACORN BIOVENTURES, L.P. (1766853) Filed by
Jasper Therapeutics (1788028) Subject
Form SCHEDULE 13G
12/02/2025 6:06 AM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 4:22 PM
Jasper Therapeutics (1788028) Subject
Qiming U.S. Healthcare Fund II, L.P. (1765710) Filed by
Form SCHEDULE 13G/A
11/12/2025 12:04 PM
Jasper Therapeutics (1788028) Subject
KINGDON CAPITAL MANAGEMENT, L.L.C. (1000097) Filed by
Form SCHEDULE 13G/A
11/10/2025 7:05 AM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/10/2025 7:17 AM
Jasper Therapeutics (1788028) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/07/2025 11:45 AM
Jasper Therapeutics (1788028) Subject
MORGAN STANLEY (895421) Filed by
Form SCHEDULE 13G/A
09/24/2025 3:01 PM
Jasper Therapeutics (1788028) Issuer
Shizuru Judith Anne (1883000) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 3:01 PM
Jasper Therapeutics (1788028) Issuer
MARTELL RON (1177079) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 3:01 PM
Jasper Therapeutics (1788028) Issuer
Lucas Svetlana (1781292) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 3:01 PM
Jasper Therapeutics (1788028) Issuer
WIGGANS THOMAS G (1208907) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2025 4:07 PM
Jasper Therapeutics (1788028) Subject
Velan Capital Investment Management LP (1848809) Filed by
Form SCHEDULE 13D/A
09/19/2025 3:35 PM
Jasper Therapeutics (1788028) Filer
Form 424B5
09/19/2025 3:38 PM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/18/2025 3:45 PM
Jasper Therapeutics (1788028) Filer
Form 424B5
07/17/2025 7:12 PM
BlackRock, Inc. (2012383) Filed by
Jasper Therapeutics (1788028) Subject
Form SCHEDULE 13G/A
07/11/2025 11:30 AM
Jasper Therapeutics (1788028) Subject
KINGDON CAPITAL MANAGEMENT, L.L.C. (1000097) Filed by
Form SCHEDULE 13G
07/09/2025 7:05 AM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/07/2025 6:35 AM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/03/2025 3:24 PM
EMSTER KURT VON (1252524) Reporting
Jasper Therapeutics (1788028) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2025 3:25 PM
Brun Scott C. (1863614) Reporting
Jasper Therapeutics (1788028) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2025 5:19 AM
Jasper Therapeutics (1788028) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/06/2025 5:23 AM
Jasper Therapeutics (1788028) Issuer
Tucker Edwin Jonathan (1792296) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 5:25 AM
CROSS HERB (1230721) Reporting
Jasper Therapeutics (1788028) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 5:27 AM
Jasper Therapeutics (1788028) Issuer
Mahal Jeetinder Singh (1882877) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 5:30 AM
Jasper Therapeutics (1788028) Issuer
MARTELL RON (1177079) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 7:00 AM
Jasper Therapeutics (1788028) Filer
Form DEF 14A
05/19/2025 7:02 AM
Jasper Therapeutics (1788028) Filer
Form DEFA14A
05/19/2025 7:04 AM
Jasper Therapeutics (1788028) Filer
Form ARS
(Data available from 1/1/2016 forward)

Jasper Therapeutics SEC Filings - Frequently Asked Questions

Jasper Therapeutics (JSPR) has submitted 254+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Jasper Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 8-K submitted on March 30, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:JSPR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners